- Home
- Research
- Inflammation
- In Vitro Digestive-Enzyme Inhibition and Antiglycation Activity of Cannabis sativa L. Essential Oil: Experimental Evaluation and Molecular Docking Analysis.
Cannabis essential oil shows enzyme inhibition in lab tests, not proven…
In Vitro Digestive-Enzyme Inhibition and Antiglycation Activity of Cannabis sativa L. Essential Oil: Experimental Evaluation and Molecular Docking Analysis.
AI Summary
The study asked whether Cannabis sativa essential oil (CSEO) can inhibit digestive enzymes and reduce the formation of glycation products. Researchers characterized the oil’s volatile compounds and tested it in vitro against α-amylase, α-glucosidase, and pancreatic lipase, and for antiglycation activity. The oil had a complex terpenoid profile, with β-caryophyllene as its main constituent; the abstract also reports several other constituents with percentages, but does not provide a quantitative measure of the oil’s enzyme-inhibiting or antiglycation effects.
CSEO showed inhibitory activity against all three enzymes and antiglycation activity at different stages of glycation-product formation. Molecular docking suggested that several major sesquiterpenes could interact with the enzyme targets, while ADME analyses provided predictions about constituent properties. These are laboratory and computational findings, not evidence of effects in people. This abstract-based summary cannot establish biological relevance, safety, or potential benefit; the authors call for further in vivo and mechanistic research.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Inflammation research papers you might find interesting.
A small evidence base leaves cannabinoid effects on RA pain uncertain
Targeted CB2 drug delivery reduced mouse plaque deposits, with sex differences
Review finds promise in acidic cannabinoids, but human benefits remain unproven
Explore More Research
Stay informed about the latest cannabis science.